New hope for hepatitis d: experimental drug enters final testing phase
NCT ID NCT07309380
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests a drug called hepalatide (L47) in 150 people with chronic hepatitis D, a serious liver disease. Participants receive either the drug or a placebo daily for 48 weeks. The goal is to see if hepalatide can lower virus levels and normalize liver enzymes. After the main phase, all participants can choose to receive the drug in an open-label follow-up.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Hepalatide (also called L47)
What this could lead to
If successful, this could provide a new treatment option for chronic hepatitis D, potentially controlling the virus and improving liver function.
What could go wrong
This is an early-stage Phase 3 trial with only 150 participants. The drug may not work better than placebo, and side effects are possible. Long-term benefits are not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS D, CHRONIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
First Hospital of Jilin University
Changchun, Jilin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••